‘New era’ of precision medicine for children with cancer
only 7% of children with targetable mutations were able to access the appropriate adult drug in a study.
Read More
Tag: paediatric
Xarelto success in paediatric venous thromboembolism
The full findings of the study were presented during a late-breaking session at the 27th Congress of the International Society on Thrombosis and Haemostasis.
Read More
Pfizer to invest £5M in paediatric medicines
The news coincides with the Medicines Manufacturing Industry Partnership (MMIP) annual conference.
Read More
AZ’s Selumetinib granted US Breakthrough Therapy Designation
The BTD is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1).
Read More
EU approves Gilenya for paediatric MS
European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
Read More
FDA approves Novartis’ Gilenya for paediatric use
US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
Read More
Novartis’ Gilenya hits targets in paediatric MS trial
Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
Read More
AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s
An experimental therapy being developed by AbbVie for paediatric patients with Crohn’s disease has been awarded Orphan Drug status in the US.
Read More
FDA OKs paediatric use of Amgen’s Blincyto
US regulators have issued an accelerated approval for use of Amgen’s immunotherapy Blincyto to treat paediatric patients with a rare form of leukaemia.
Read More
NHS paediatric workforce ‘at breaking point’
Doctors are warning that UK paediatric care is at breaking point because of growing staff shortages across the country.
Read More
FDA expands use of Novartis/Genentech’s asthma drug
US regulators have approved an expanded age range for Novartis/Genentech’s Xolair, giving younger children with moderate to severe persistent asthma a new option to help control their disease.
Read More
EU allows paediatric use of Shire’s Restive
European regulators have approved the use of Shire’s Restive in children with short bowel syndrome (SBS), a rare and potentially life-threatening gastrointestinal condition.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
